肿瘤细胞裂解物—结核分枝杆菌热休克蛋白65的抗肺癌作用
|
摘要
肿瘤细胞裂解物(TCL)是利用一定物理或者化学的方法将肿瘤细胞裂解,使细胞内的抗原物质释放到外周而形成的抗原肽混合物。理论上TCL中含有肿瘤细胞内的全部肿瘤抗原,因此除可以作为抗肿瘤疫苗应用于抗肿瘤治疗外,还能有效的解决目前的抗肿瘤疫苗抗原性比较单一的问题。但是,以外源性的方式免疫肿瘤抗原存在不能很好激活细胞免疫反应的问题,而解决这一问题的关键是如何使抗原物质更好的活化特异性CTL。要作到这一点,首先应该想办法使外源性应用的抗原被APC以MHC I途径递呈。目前的研究已经发现一些免疫细胞,如树突状细胞(DC)等,可以利用交叉递呈的机制将外源性抗原以MHC I类途径进行递呈,从而有效的诱生抗原特异性CTL。而这一过程的发生通常需要一些免疫佐剂物质的辅助。大量的实验事实已经证明热休克蛋白(HSP)就是这样一种可以辅助交叉递呈发生的物质,因此利用它和肿瘤抗原共同诱导抗肿瘤免疫应该是可行的肿瘤治疗策略。在本研究中,我们直接在体外将MHSP65和Lewis肺癌TCL混合制备出MHSP65-TCL抗肿瘤疫苗并探索了其对Lewis肺癌的治疗效果。结果发现,MHSP65-TCL可以在C57BL/6小鼠体内产生明显的抑制Lewis肺癌细胞生长的作用,并显著延长小鼠的生存期(P<0.05)。我们接下来的研究表明,这种抗肺癌的效果是由TCL特异性的CTL细胞所介导的,小鼠体内活化的CTL细胞可以在体外明显的杀伤Lewis肺癌细胞(P<0.05)。此外,我们还发现非特异性免疫在抗肿瘤过程中也发挥了重要的作用。MHSP65-TCL正是通过激活特异性免疫和非特异性免疫这两条途径来发挥抗肺癌作用的。因此,这种新型的抗肿瘤疫苗将很有希望应用于肺癌的免疫治疗。
The research on anti-tumor immunity has a long history. For several decades, immune mechanism of tumor’s incidence,development and metastasis have been explored and illuminated. People have gradually recognized the correlation of tumor disease and immunology,and actively applied theory on anti-tumor practice. Especially recent years,anti-tumor researches have achieved a new phase with the finding and applying of tumor specific antigen and tumor non-specific antigen. Using different tumor antigens as anti-tumor vaccine,people can cure tumor disease more directly and obtain anti-tumor effect aiming at tumor cells,which can overcome the disadvantage of present anti-tumor measures have more side effects and poor specific. However,the targets of today’s anti-tumor vaccine are simplex,which can’t induce powerful enough and unlimited anti-tumor effect. To induce more strengthen and complete anti-tumor immunity,we need to combine several kinds of tumor antigens or directly produce the immunogen containing many tumor antigens.
To include more tumor antigens,the normal method is irradiating tumor cells with X-ray and then immunizing the tumor cells as an immunogen into human body. But some researches have found that this therapy method has some risks,because the irradiated tumor cells still have the possibility of tumorigenesis. The research of Donna H.D and his colleges had found that the tumor cells irradiated by X-ray couldn’t be completely killed,and some parts of the tumor cells had the ability of division and proliferation. Another strategy is using tumor cell lysate as immunogen (TCL). TCL is tumor antigens mixture prepared by lysis tumor cells with physical or chemical methods. Theoretically,TCL contains all the tumor antigens in tumor cells. Except using as an anti-tumor vaccine to applying on tumor therapy,TCL can solve the problem that present anti-tumor vaccine’s antigenicity is simplex.
Besides prepareing effective immunogen,there is a problem that tumor antigen immunized exogenously can’t effectively activate cellular immunity should be solved. That is because tumor antigens immunized exogenously usually are presented by antigen present cell (APC) in MHC II pathway priming humoral immunity producing specific antibody. But antigen specific cytotoxicity T lymphocyte (CTL) will play a key role in anti-tumor immunity rather than antigen specific antibody. Based on this fact,the key point of tumor antigen immunized exogenously priming effective anti-tumor immunity is activating CTL effectively. To achieve this goal,the problem how tumor antigen immunized exogenously can be presented by APC in MHC I pathway should be solved at first,because basic immunology has illuminated that CTL’s activation must depend on the combination of tumor antigen peptides and MHC I cell surface molecular. Some researches have found that some immune cells,like dendritic cell (DC),can cross-present exogenous tumor antigen in MHC I pathway priming activation of antigen specific CTL. In this process,some immune adjuvant is needed helping the tumor antigens to be presented. Many evidences have proved that heat shock protein (HSP) is a kind of protein can assist tumor antigens to be cross-presented. Thus,combining HSP and tumor antigen is a feasible anti-tumor strategy. Tumor-derived chaperone-rich cell lysate (CRCL) prepared via a free solution-isoelectric focusing (FS-IEF) technique were demonstrated therapeutic and prophylactic in mice against B-16 melonoma , leukemia (12B1) and B-cell leukemia/lymphoma (A20). A cellular vaccine prepared by combining the CRCL preparations with dendritic cells could eradicate pre-existing tumors in a high percentage of cases. In addition,recombinant HSP fusion proteins between tumor antigens and HSPs were developed as tumor vaccines. A HSP65-MUC I fusion protein between mycobacterial HSP65 (MHSP65) and MUC1 derived peptide was demonstrated capable of inducing MUC1 specific CTL that contributed to the growth inhibition of B-16 melonomas in mice. Another fusion protein between MHSP65 and human papillomavirus (HPV) E7 derived peptide was tested in clinical trials to treat HPV associated diseases. Alternatively , tumor cell lysate-pulsed human monocyte-derived DCs heat-shocked were found increased in their capacity to generate CTL responses against medullary thyroid carcinoma (MTC) tumor cells in vitro,showing that heat shocking DCs,due to the expression of HSPs,may be a kind of efficient tumor vaccines. In our research,we combined MHSP65 and TCL from Lewis lung cancer cells producing MHSP65-TCL anti-tumor vaccine and investigated its anti-tumor immunity.
1. The expression and purification of MHSP65 and the preparation of TCL or MHSP65-TCL
To obtain MHSP65 used in the development of anti-tumor vaccine and the following experiments in vivo and vitro,we firstly constructed a pET28a-HSP65 recombinant plasmid and expressed MHSP65 protein in BL21 escherichia coli. Then we purified the MHSP65 protein using Ni+ affinity chromatography method. The level of LPS in purified MHSP65 protein should be detected. Only when the detected results accorded with the standard LPS level,the MHSP65 could be used in immunization in vivo and cell experiment in vitro. The results of SDS-PAGE detection,protein quantitation and western blot detection showed that we successfully expressed and purified the MHSP65. The purity of this protein was over 90%,and the concentration of this protein was 330μg/ml. The level of LPS in MHSP65 was lower than. This purified protein corresponded with the requirement of following experiments.
To preparing TCL,we froze and thawed between -70℃and 37℃for 5 times. Our results exhibited that all the Lewis lung caner cells were destroyed after the freezing and thawing and stained into blue by trypan blue under microscope. Protein quantitation and SDS-PAGE revealed that all the protein in tumor cells had released out of the cells,and the concentration of this protein solution is 3.15mg/ml,which achieved our expect preparing a more safer tumor antigen peptides mixture.
To preparing MHSP65-TCL,we directly mixed MHSP65 and TCL in vitro. Some researched have proved that direct mixing antigen and MHSP65 can effectively induce anti-tumor effect. So in our research,we directly mixed TCL from 1×10~6 Lewis lung cancer cells and MHSP65 in 0.85% NaCl producing MHSP65-TCL used in following experiments.
2. Investigation of TCL or MHSP65-TCL’s component
To explore the component of TCL and MHSP65-TCL,we carried on degenerated SDS-PAGE electrophoresis analysis with different components in TCL or MHSP65-TCL.Besides that , we carried on non-degenerated SDS-PAGE electrophoresis analysis and Western blot detection with different components in MHSP65-TCL. The results showed that TCL contained various proteins with different molecular weight,which equably distributed in cell lysate and cell precipitation. In MHSP65-TCL,MHSP65 couldn’t be digested by the hydrolytic enzyme probably existed in TCL,and maintaining the integrity of its structures. Moreover we detected a kind of MHSP65-tumor antigen complex in MHSP65-TCL by non-degenerate SDS-PAGE and Western blot analysis,and the formation of this complex didn’t correlated with the mixing time of MHSP65 and TCL. Some researches have proved that this complex may be the structure basis on which MHSP65 helps exogenous antigens to be cross-presented. These results suggested that TCL we prepared contained a large number of intra-cellular peptides. Besides that,there were MHSP65-tumor antigen complexes existed in MHSP65-TCL,which play a crucial role in inducing specific anti-tumor immunity.
3. MHSP65-TCL induced anti-Lewis lung cancer effect in mice
To test the anti-tumor effect of MHSP65-TCL , we firstly carried on tumor-suppressive experiment in mice. In the experiment,we immunized mice on day -7,1,8,15,and inoculated Lewis lung cancer tissue on day 0,then observing tumor incidence,mice living condition and measuring tumor size to draw tumor growth curve,tumor incidence curve and mice survival curve (P<0.05). The results showed that immunization of MHS65-TCL could significantly inhibit the growth of Lewis lung cancer in mice (P<0.05),whereas MHSP65 or TCL immunization didn’t exhibit such anti-tumor effect. By the results of tumor incidence,we found that tumor incidence of NaCl injected,TCL immunized,MHSP65 immunized mice had arrived 66.67%,50% and 83.33% separately,whereas that of MHS65-TCL immunized mice was only 16.67% on day 11 after tumor challenge. By the results of mice survival,we found that 100% MHSP65-TCL immunized mice survived,whereas 83.33% NaCl injected mice had dead on day 50. These results suggested that MHSP65-TCL immunization could significantly delay Lewis lung cancer incidence,prevented tumor’s growth and prolong the survival of mice. Following that,we investigated the immunizing dose of MHSP65 in MHSP65-TCL and the immunizing schedule in vivo. Compared with control groups,TCL or MHSP65 immunization couldn’t inhibit the growth of tumor (P>0.05),whereas all 1μg MHSP65,10μg MHSP65,100μg MHSP65 plus 1×10~6 TCL immunization had anti-Lewis lung cancer effect (P<0.05). Among them,1μg MHSP65 and 10μg MHSP65 plus 1×10~6 TCL immunization induced more powerful anti-tumor immunity (p<0.001) than 100μg MHSP65 plus 1×10~6 TCL immunization (P=0.004). Compared with the schedule immunizing after tumor challenge,immunizing before and after tumor challenge obtained better anti-tumor effect (P=0.014).
4. MHSP65-TCL induced specific anti-lung cancer immunity
To investigate the role of specific immunity in anti-tumor process,we detected activation status of CD8+ T cells and their cytotoxicity. To detect CD8+ T cells in mice,we immunized mice on day 0,7,14,20 and sacrificed the mice on day 15,19,21. Then spleen cells were taken and stained with FITC anti-CD8 and PE anti-CD69 mAb to analysis by flow cytometer. The results showed that activated CD8+ T cells in splenocytes from MHSP65-TCL immunized mice significantly decreased on day 19 (P<0.01) and didn’t show any difference on day 15 or 21 ( P>0.05). We considered this result might correlate with the migration of CTL and memory CTL weren’t activated effectively. When recalled in vitro with TCL,activated CD8+ T cells in splenocytes from MHSP65-TCL immunized mice significantly increased compared with that in splenocytes from NaCl injected,TCL immunized or MHSP65 immunized mice (P=0.001). Following that,we detected the cytotoxicity of CD8+ CTL in mouse splenocytes. The results showed that splenocytes from MHSP65-TCL immunized mice couldn’t significantly kill Lewis lung cancer cells compared with that from NaCl injected,TCL immunized and MHSP65 immunized mice in E:T ratio of 5:1 or 15:1 (P>0.05). When E:T radio is 45:1,splenocytes from MHSP65-TCL immunized mice could significantly kill Lewis lung cancer cells,and the killing rate of splenocytes from MHSP65-TCL immunized mice is 38.23 %,which is higher than that of splenocytes from NaCl injected,TCL immunized and MHSP65 immunized mice (P=0.02). These results suggested that MHSP65-TCL immunization could induce TCL specific anti-tumor effect in mice.
5. MHSP65-TCL induced non-specific anti-lung cancer immunity
To investigate non-specific anti-lung cancer immunity induced by MHSP65-TCL immunization. We detected expression of CD69 and TNF secretion in splenocytes from MHSP65-TCL immunized mice,and their cytotoxicity. Besides that,we detected the activation of NK cells in vivo and vitro. To CD69 detection,splenocytes were taken from na?ve mice,and stimulated the splenocytes with MHSP65-TCL,MHSP65,TCL or NaCl to analysis CD69’s expression. The results showed that CD69 expression of splenocytes stimulated with MHSP65-TCL was significantly higher than NaCl group and MHSP65 group (P<0.001). To TNF detection,we obtained culture supernatant of activated splenocytes to evaluate its TNF level. The results showed that there was high level TNF could kill L929 cells in vitro existed in the culture supernatant. To cytotoxicity assay of activated splenocytes , we took splenocytes as effect cells and Lewis lung cancer cells as target cells. When E:T radio is 45:1 or 15:1,splenocytes from MHSP65-TCL immunized mice could significantly kill Lewis lung cancer cells,and the killing rate of splenocytes from MHSP65-TCL immunized mice is significantly higher than that of splenocytes from NaCl injected,TCL immunized and MHSP65 immunized mice (P<0.05). To cytotoxicity assay of activated NK,we took splenocytes as effect cells and YAC-1 cells as target cells. When E:T radio is 100:1 or 50:1,splenocytes from MHSP65-TCL immunized mice could significantly kill Lewis lung cancer cells,and the killing rate of splenocytes from MHSP65-TCL immunized mice is significantly higher than that of splenocytes from NaCl injected,TCL immunized and MHSP65 immunized mice (P<0.05). To detect activated NK in vivo,we immunized mice on day 0,7,14,20 and sacrificed mice on day 6,15,19,21. Then spleen cells were taken and stained with FITC anti-CD8 and PE anti-CD69 mAb to analysis by flow cytometer. The results showed that activated CD8+ T cells in splenocytes from MHSP65-TCL immunized mice significantly increased on day 6 or 15 (P<0.01) and didn’t show any difference on day 19 or 21 ( P>0.05).
6. MHSP65-TCL produced with B16 melanoma cells induced anti-melanoma effect in mice.
Besides the anti-lung cancer effect mentioned above, we investigated the anti-tumor effect induced by MHSP65-TCL produced with B16 melanoma. Our experiments proved that MHSP65-TCL produced by combining B16 TCL and MHSP65 could induce anti-melanoma effect in mice and significantly prolong the survival of immunized mice. These initiatory results provided a new direction of MHSP65-TCL research.
Collectively,to develop effective anti-lung cancer vaccines,we directly mixed MHSP65 and TCL from Lewis lung cancer cells in vitro and tested its efficacy on stimulating anti-tumor immunity. Our results show that MHSP65-TCL immunization significantly inhibits the growth of lung cancer in mice and prolongs the survival of lung cancer bearing mice. In vivo and vitro data suggest that MHSP65-TCL could induce specific CTL responses as well as non-specific immunity,both of which contribute to the effective tumor elimination. Thus,this report provides a more easy method to prepare MHSP65-TCL anti-tumor vaccine,which might be further developed to treat lung cancer.
The research on anti-tumor immunity has a long history. For several decades, immune mechanism of tumor’s incidence,development and metastasis have been explored and illuminated. People have gradually recognized the correlation of tumor disease and immunology,and actively applied theory on anti-tumor practice. Especially recent years,anti-tumor researches have achieved a new phase with the finding and applying of tumor specific antigen and tumor non-specific antigen. Using different tumor antigens as anti-tumor vaccine,people can cure tumor disease more directly and obtain anti-tumor effect aiming at tumor cells,which can overcome the disadvantage of present anti-tumor measures have more side effects and poor specific. However,the targets of today’s anti-tumor vaccine are simplex,which can’t induce powerful enough and unlimited anti-tumor effect. To induce more strengthen and complete anti-tumor immunity,we need to combine several kinds of tumor antigens or directly produce the immunogen containing many tumor antigens.
To include more tumor antigens,the normal method is irradiating tumor cells with X-ray and then immunizing the tumor cells as an immunogen into human body. But some researches have found that this therapy method has some risks,because the irradiated tumor cells still have the possibility of tumorigenesis. The research of Donna H.D and his colleges had found that the tumor cells irradiated by X-ray couldn’t be completely killed,and some parts of the tumor cells had the ability of division and proliferation. Another strategy is using tumor cell lysate as immunogen (TCL). TCL is tumor antigens mixture prepared by lysis tumor cells with physical or chemical methods. Theoretically,TCL contains all the tumor antigens in tumor cells. Except using as an anti-tumor vaccine to applying on tumor therapy,TCL can solve the problem that present anti-tumor vaccine’s antigenicity is simplex.
Besides prepareing effective immunogen,there is a problem that tumor antigen immunized exogenously can’t effectively activate cellular immunity should be solved. That is because tumor antigens immunized exogenously usually are presented by antigen present cell (APC) in MHC II pathway priming humoral immunity producing specific antibody. But antigen specific cytotoxicity T lymphocyte (CTL) will play a key role in anti-tumor immunity rather than antigen specific antibody. Based on this fact,the key point of tumor antigen immunized exogenously priming effective anti-tumor immunity is activating CTL effectively. To achieve this goal,the problem how tumor antigen immunized exogenously can be presented by APC in MHC I pathway should be solved at first,because basic immunology has illuminated that CTL’s activation must depend on the combination of tumor antigen peptides and MHC I cell surface molecular. Some researches have found that some immune cells,like dendritic cell (DC),can cross-present exogenous tumor antigen in MHC I pathway priming activation of antigen specific CTL. In this process,some immune adjuvant is needed helping the tumor antigens to be presented. Many evidences have proved that heat shock protein (HSP) is a kind of protein can assist tumor antigens to be cross-presented. Thus,combining HSP and tumor antigen is a feasible anti-tumor strategy. Tumor-derived chaperone-rich cell lysate (CRCL) prepared via a free solution-isoelectric focusing (FS-IEF) technique were demonstrated therapeutic and prophylactic in mice against B-16 melonoma , leukemia (12B1) and B-cell leukemia/lymphoma (A20). A cellular vaccine prepared by combining the CRCL preparations with dendritic cells could eradicate pre-existing tumors in a high percentage of cases. In addition,recombinant HSP fusion proteins between tumor antigens and HSPs were developed as tumor vaccines. A HSP65-MUC I fusion protein between mycobacterial HSP65 (MHSP65) and MUC1 derived peptide was demonstrated capable of inducing MUC1 specific CTL that contributed to the growth inhibition of B-16 melonomas in mice. Another fusion protein between MHSP65 and human papillomavirus (HPV) E7 derived peptide was tested in clinical trials to treat HPV associated diseases. Alternatively , tumor cell lysate-pulsed human monocyte-derived DCs heat-shocked were found increased in their capacity to generate CTL responses against medullary thyroid carcinoma (MTC) tumor cells in vitro,showing that heat shocking DCs,due to the expression of HSPs,may be a kind of efficient tumor vaccines. In our research,we combined MHSP65 and TCL from Lewis lung cancer cells producing MHSP65-TCL anti-tumor vaccine and investigated its anti-tumor immunity.
1. The expression and purification of MHSP65 and the preparation of TCL or MHSP65-TCL
To obtain MHSP65 used in the development of anti-tumor vaccine and the following experiments in vivo and vitro,we firstly constructed a pET28a-HSP65 recombinant plasmid and expressed MHSP65 protein in BL21 escherichia coli. Then we purified the MHSP65 protein using Ni+ affinity chromatography method. The level of LPS in purified MHSP65 protein should be detected. Only when the detected results accorded with the standard LPS level,the MHSP65 could be used in immunization in vivo and cell experiment in vitro. The results of SDS-PAGE detection,protein quantitation and western blot detection showed that we successfully expressed and purified the MHSP65. The purity of this protein was over 90%,and the concentration of this protein was 330μg/ml. The level of LPS in MHSP65 was lower than. This purified protein corresponded with the requirement of following experiments.
To preparing TCL,we froze and thawed between -70℃and 37℃for 5 times. Our results exhibited that all the Lewis lung caner cells were destroyed after the freezing and thawing and stained into blue by trypan blue under microscope. Protein quantitation and SDS-PAGE revealed that all the protein in tumor cells had released out of the cells,and the concentration of this protein solution is 3.15mg/ml,which achieved our expect preparing a more safer tumor antigen peptides mixture.
To preparing MHSP65-TCL,we directly mixed MHSP65 and TCL in vitro. Some researched have proved that direct mixing antigen and MHSP65 can effectively induce anti-tumor effect. So in our research,we directly mixed TCL from 1×10~6 Lewis lung cancer cells and MHSP65 in 0.85% NaCl producing MHSP65-TCL used in following experiments.
2. Investigation of TCL or MHSP65-TCL’s component
To explore the component of TCL and MHSP65-TCL,we carried on degenerated SDS-PAGE electrophoresis analysis with different components in TCL or MHSP65-TCL.Besides that , we carried on non-degenerated SDS-PAGE electrophoresis analysis and Western blot detection with different components in MHSP65-TCL. The results showed that TCL contained various proteins with different molecular weight,which equably distributed in cell lysate and cell precipitation. In MHSP65-TCL,MHSP65 couldn’t be digested by the hydrolytic enzyme probably existed in TCL,and maintaining the integrity of its structures. Moreover we detected a kind of MHSP65-tumor antigen complex in MHSP65-TCL by non-degenerate SDS-PAGE and Western blot analysis,and the formation of this complex didn’t correlated with the mixing time of MHSP65 and TCL. Some researches have proved that this complex may be the structure basis on which MHSP65 helps exogenous antigens to be cross-presented. These results suggested that TCL we prepared contained a large number of intra-cellular peptides. Besides that,there were MHSP65-tumor antigen complexes existed in MHSP65-TCL,which play a crucial role in inducing specific anti-tumor immunity.
3. MHSP65-TCL induced anti-Lewis lung cancer effect in mice
To test the anti-tumor effect of MHSP65-TCL , we firstly carried on tumor-suppressive experiment in mice. In the experiment,we immunized mice on day -7,1,8,15,and inoculated Lewis lung cancer tissue on day 0,then observing tumor incidence,mice living condition and measuring tumor size to draw tumor growth curve,tumor incidence curve and mice survival curve (P<0.05). The results showed that immunization of MHS65-TCL could significantly inhibit the growth of Lewis lung cancer in mice (P<0.05),whereas MHSP65 or TCL immunization didn’t exhibit such anti-tumor effect. By the results of tumor incidence,we found that tumor incidence of NaCl injected,TCL immunized,MHSP65 immunized mice had arrived 66.67%,50% and 83.33% separately,whereas that of MHS65-TCL immunized mice was only 16.67% on day 11 after tumor challenge. By the results of mice survival,we found that 100% MHSP65-TCL immunized mice survived,whereas 83.33% NaCl injected mice had dead on day 50. These results suggested that MHSP65-TCL immunization could significantly delay Lewis lung cancer incidence,prevented tumor’s growth and prolong the survival of mice. Following that,we investigated the immunizing dose of MHSP65 in MHSP65-TCL and the immunizing schedule in vivo. Compared with control groups,TCL or MHSP65 immunization couldn’t inhibit the growth of tumor (P>0.05),whereas all 1μg MHSP65,10μg MHSP65,100μg MHSP65 plus 1×10~6 TCL immunization had anti-Lewis lung cancer effect (P<0.05). Among them,1μg MHSP65 and 10μg MHSP65 plus 1×10~6 TCL immunization induced more powerful anti-tumor immunity (p<0.001) than 100μg MHSP65 plus 1×10~6 TCL immunization (P=0.004). Compared with the schedule immunizing after tumor challenge,immunizing before and after tumor challenge obtained better anti-tumor effect (P=0.014).
4. MHSP65-TCL induced specific anti-lung cancer immunity
To investigate the role of specific immunity in anti-tumor process,we detected activation status of CD8+ T cells and their cytotoxicity. To detect CD8+ T cells in mice,we immunized mice on day 0,7,14,20 and sacrificed the mice on day 15,19,21. Then spleen cells were taken and stained with FITC anti-CD8 and PE anti-CD69 mAb to analysis by flow cytometer. The results showed that activated CD8+ T cells in splenocytes from MHSP65-TCL immunized mice significantly decreased on day 19 (P<0.01) and didn’t show any difference on day 15 or 21 ( P>0.05). We considered this result might correlate with the migration of CTL and memory CTL weren’t activated effectively. When recalled in vitro with TCL,activated CD8+ T cells in splenocytes from MHSP65-TCL immunized mice significantly increased compared with that in splenocytes from NaCl injected,TCL immunized or MHSP65 immunized mice (P=0.001). Following that,we detected the cytotoxicity of CD8+ CTL in mouse splenocytes. The results showed that splenocytes from MHSP65-TCL immunized mice couldn’t significantly kill Lewis lung cancer cells compared with that from NaCl injected,TCL immunized and MHSP65 immunized mice in E:T ratio of 5:1 or 15:1 (P>0.05). When E:T radio is 45:1,splenocytes from MHSP65-TCL immunized mice could significantly kill Lewis lung cancer cells,and the killing rate of splenocytes from MHSP65-TCL immunized mice is 38.23 %,which is higher than that of splenocytes from NaCl injected,TCL immunized and MHSP65 immunized mice (P=0.02). These results suggested that MHSP65-TCL immunization could induce TCL specific anti-tumor effect in mice.
5. MHSP65-TCL induced non-specific anti-lung cancer immunity
To investigate non-specific anti-lung cancer immunity induced by MHSP65-TCL immunization. We detected expression of CD69 and TNF secretion in splenocytes from MHSP65-TCL immunized mice,and their cytotoxicity. Besides that,we detected the activation of NK cells in vivo and vitro. To CD69 detection,splenocytes were taken from na?ve mice,and stimulated the splenocytes with MHSP65-TCL,MHSP65,TCL or NaCl to analysis CD69’s expression. The results showed that CD69 expression of splenocytes stimulated with MHSP65-TCL was significantly higher than NaCl group and MHSP65 group (P<0.001). To TNF detection,we obtained culture supernatant of activated splenocytes to evaluate its TNF level. The results showed that there was high level TNF could kill L929 cells in vitro existed in the culture supernatant. To cytotoxicity assay of activated splenocytes , we took splenocytes as effect cells and Lewis lung cancer cells as target cells. When E:T radio is 45:1 or 15:1,splenocytes from MHSP65-TCL immunized mice could significantly kill Lewis lung cancer cells,and the killing rate of splenocytes from MHSP65-TCL immunized mice is significantly higher than that of splenocytes from NaCl injected,TCL immunized and MHSP65 immunized mice (P<0.05). To cytotoxicity assay of activated NK,we took splenocytes as effect cells and YAC-1 cells as target cells. When E:T radio is 100:1 or 50:1,splenocytes from MHSP65-TCL immunized mice could significantly kill Lewis lung cancer cells,and the killing rate of splenocytes from MHSP65-TCL immunized mice is significantly higher than that of splenocytes from NaCl injected,TCL immunized and MHSP65 immunized mice (P<0.05). To detect activated NK in vivo,we immunized mice on day 0,7,14,20 and sacrificed mice on day 6,15,19,21. Then spleen cells were taken and stained with FITC anti-CD8 and PE anti-CD69 mAb to analysis by flow cytometer. The results showed that activated CD8+ T cells in splenocytes from MHSP65-TCL immunized mice significantly increased on day 6 or 15 (P<0.01) and didn’t show any difference on day 19 or 21 ( P>0.05).
6. MHSP65-TCL produced with B16 melanoma cells induced anti-melanoma effect in mice.
Besides the anti-lung cancer effect mentioned above, we investigated the anti-tumor effect induced by MHSP65-TCL produced with B16 melanoma. Our experiments proved that MHSP65-TCL produced by combining B16 TCL and MHSP65 could induce anti-melanoma effect in mice and significantly prolong the survival of immunized mice. These initiatory results provided a new direction of MHSP65-TCL research.
Collectively,to develop effective anti-lung cancer vaccines,we directly mixed MHSP65 and TCL from Lewis lung cancer cells in vitro and tested its efficacy on stimulating anti-tumor immunity. Our results show that MHSP65-TCL immunization significantly inhibits the growth of lung cancer in mice and prolongs the survival of lung cancer bearing mice. In vivo and vitro data suggest that MHSP65-TCL could induce specific CTL responses as well as non-specific immunity,both of which contribute to the effective tumor elimination. Thus,this report provides a more easy method to prepare MHSP65-TCL anti-tumor vaccine,which might be further developed to treat lung cancer.
引文
[1] Adhikari A S, Sridhar R K, Rangaraj N, et al. Heat stress-induced localization of small heat shock proteins in mouse myoblasts: intranuclear lamin APC speckles as target for alphaB2crystallin and Hsp25 [J]. Exp Cell Res, 2004, 299(2): 393-403.
[2] Ai J H, Yang Z, Qiu F Z, et al. Heat shock protein 90 is responsible for hyperdynamic circulation in portal hypertensive rats [J]. World J Gastroenterol, 2003, 9(11):2544-2547.
[3] Alard J E, Dueymes M, Youinou P, et al. Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases [J]. Autoimmun Rev, 2007, 6:438-443.
[4] Albanell J, Codony J, Rovira A, et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4 [J]. Adv Exp Med Biol, 2003, 532:2532-2551.
[5] Amato R J. Renal cell carcinoma:review of novel single-agent therapeutics and combination regimens [J]. Ann Oncol, 2005, 16(1):7-15.
[6] Antonia S, MuléJ J, Weber J S. Current developments of immunotherapy in the clinic [J]. Curr Opin Immunol, 2004, 16(2):130- 136.
[7] Arrigo A P, Firdaus WJ, Mellier G, et al. Cytotoxic effects induced by oxidative stress in cultured mammalian cells and protection provided by Hsp27 expression [J]. Methods, 2005, 35(2):126-138.
[8] Assikis V J, Daliani D, Logothetis C, et al. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC) [J]. Proc Am Soc Clin Oncol, 2003, 22:386-393.
[9] Ayada K, Yokota K, Kobayashi K, et al. Chronic infections and atherosclerosis [J]. Ann N Y Acad Sci, 2007, 1108:594-602.
[10] Banchereau J, Palucka A K. Dendritic cells as therapeutic vaccines against cancer [J]. Nat Rev Immunol, 2005, 5(4):296-306.
[11] Barral J M, Broadley S A, Schaffar G, et al. Roles of molecular chaperones in protein misfolding diseases [J]. Semin Cell Dev Biol, 2004, 15:17-29.
[12] Basha E, Friedrich K L, Vierling E. The N-terminal arm of small heat shock proteins is important for both chaperone activity and substrate specificity [J]. J Biol Chem, 2006, 281(52):39943-39952.
[13] Basha E, Lee G J, Demeler B, et al. Chaperone activity of cytosolic small heat shock proteins fromwheat [J]. Eur J Biochem, 2004, 271(8):1426-1436.
[14] Bech M, Plm II, Welch W J. Interaction of folding and assen by events [J]. Science, 1990, 248:850-854.
[15] Behboudi S, Morein B, Villacres E M. In vitro activation of antigen p resenting cells (APC) by defined composition of quillaja saponaria molina triterpenoids [J]. Clin Exp Immunol, 1996, 105:26-30.
[16] Beliakof J, Bagatel R, Paine M G, et al. Hormone refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors [J]. Clin Cancer Res, 2003, 9(13):4961-4971.
[17] Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings [J]. J Clin Oncol, 2002, 20(20):4169-4180.
[18] Bendandi M, Rodríguez-Calvillo M, Inogés S, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation [J]. Leuk Lymphoma, 2006, 47(1):29-37.
[19] Bergstrom M M, Lovgren K, Akerblom L. Antigen specific increases in the number of splenocyttes expressing MHC classⅡmolecules following restimulation with antigen in various physical forms [J]. Scand J Immunol, 1992, 36:565-574.
[20] Blachere N E, Li Z L, Chandawarkar R Y, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity [J]. J Exp Med, 1997, 186:1315-1322.
[21] Blachere N E, Udono H, Janetzki S, et al. Heat shock protein vaccinesagainst cancer [J]. J Immunother, 1993, 14:352-356.
[22] Bradbury, Penelope A, Shepherd, Immunotherapy for Lung Cancer [J]. FRCPC, 2008, 3(6):164-170.
[23] Butts C, Murray N, Maksymiuk A. Randomized phase IIB trial of BLP25 liposome vaccine instage IIIB and IV non-small cell lung cancer [J]. J Clin Oncol, 2005, 23(27):6674-6681.
[24] Capdeville R, Silberman S. Imatinib: a targeted clinical drug development [J]. Semin Hematol, 2003, 40(2):15-20.
[25] Carmody R J, Chen Y H. Nuclear factor-kappaβ: activation and regulation during toll-like receptor signaling [J]. Cell Mol Immunol, 2007, 4:31-41.
[26] Carolina M, Keith H, David S. L. Heat shock proteins hsp90 and hsp70 protect neuronal cells from thermal stress but not from programmed cell death. [J] Neuro Chem, 1994, 63:1787-1795.
[27] Cerundolo V, Hermans I F, Salio M. Dendritic cells:a journey from laboratory to clinic [J]. Nat Immunol, 2004, 5(1):7-10.
[28] Chandawarkar R Y, Wagh M S, Srivastava P K. The dual nature of specific immunological activity of tumor-derived gp96 preparations [J]. J Exp Med, 1999, 189(9):1437-1442.
[29] Chen W, Syldath U, Bellmannk, et al. Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System[J]. J Immunol, 1999, 162(6):3212-3219.
[30] Chu N R,Wu H B, Wu T C, et al. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7 [J]. Cell Stress & Chaperones,2000,5(5):401-405.
[31] Ciupitu A T, Petersson M, Donnell C L, et al. Immunization with a lymphocytic choriomeningitisvirus peptide mixed with heat shock protein 70 resultsin protective antiviral immunity and specific cytotoxic T lymphocytes [J]. J Exp Med, 1998, 187:685-691.
[32] Conry R M, Curiel D T, Strong T V, et al. Safety and immunogenicity of aDNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients [J]. Clin Cancer Res, 2002, 8(9): 2782-2787.
[33] Curti A, Tosi P, Comoli P, et al. PhaseⅠ/Ⅱclinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides [J]. Br J Haematol, 2007, 139(3):415-424.
[34] Dadabayev A R, Wang Z, Zhang Y, et al. Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics? [J]. Am J Hematol, 2005, 80(1):6-11.
[35] Daniel P S, Abba I T, Tristram G P. Basic & Clinical Immunology, 8 th ed [M]. East Norwalk: Prentice Hall International Inc, 1994:51-52.
[36] Dapeng L, Hui L, Peiyin Z, et al. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity [J]. Eur J Immunol, 2006, 36: 1324-1336.
[37] David S, Manuel G, Francisco S M. CD69 is an immunoregulatory molecule induced following activation [J]. Trends Immunol, 2005, 26(3): 136-140.
[38] De Cerio A L, Zabalegui N, Rodríguez C M, et al. Anti-idiotype antibodies in cancer treatment [J]. Oncogene, 2007, 26(25):3594-602.
[39] Den E J, Bennink E J, Doerwald L, et al. Mimicking phosphorylation of the small heat-shock protein alphaB-crystallin recruits the F-box protein FBX4 to nuclear SC35 speckles [J]. Eur J Biochem, 2004, 271(21):4195-4203.
[40] Deocaris CC, Kaul SC, Wadhwa R. On the brotherhood of the mitochondrial chaperonesmortalin and heat shock protein 60 [J]. Cell Stress Chaperones, 2006, 11:116-128.
[41] Donna H D, Kevin T H, Erin M S, et al. The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines [J]. BMC Cancer, 2008, 8(12):360-871.
[42] Dotsika E, Karagouni E, Sundquist B et al. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein Barr virusISCOMs [J]. Scand J Immunol, 1997, 45:261-268.
[43] Dresses R, Dlsner L, Quentin T, et al. Heat shock protein 70 is able to prevent heat shock-jnduced resistance of tragel cells to CTL [J]. J Immunol, 2000, 164(5):2362-2371.
[44] Dudley M E, Wunderlich J R, Yang J C, et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J]. Clin Oncol, 2005, 23(10):2346-2357.
[45] Dunn G P, Bruce A T, Ikeda H, et al. Cancer immunoediting:from immunosurveillance to tumor escape [J]. Nat Immunol, 2002, 3(11):991-998.
[46] Evel K K, Chen S Y. Dendritic cell-based tumor vaccines and antigen presentation attenuators [J]. Mol Ther, 2006, 13(5):850-858.
[47] Faried A, Sohda M, Nakajima M, et al. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma [J]. Eur J Cancer, 2004, 40(18):2804-2811.
[48] Feng H, Zeng Y, Graner M W, et al. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood, 2003, 101:245-252.
[49] Finn O J. Cancer vaccines: between the idea and the reality [J]. Nat Rev Immunol, 2003, 3(8):630-641.
[50] Gang L, Samita A, Gustavo H, et al. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model [J]. Mol Cancer Ther, 2008, 7(3):721-729.
[51] Garcia M, Jemal A, Ward E M, et al. Global Cancer Facts & Figures 2007 [J]. American Cancer Society, 2007, 20:1-52.
[52] Garia S N. Net results of nucleolar dynamics [J]. Cell, 1999, 97:825-828.
[53] Georges H W, Pierre J. Immunostimulating agents: what next? A review of their present and potentialmedical applications [J]. Eur J Biochem, 1996, 242(1):1-19.
[54] Gilboa E. DC-based cancer vaccines [J]. J Clin Invest, 2007, 117(5):1195-1203.
[55] Gorre M E, Mohammed M, Ellwood K, et al. Clinical resistance to STl2571 cancer therapy caused by BCR2 ABL gene mutation or amplification [J]. Science, 2001, 293(5531):876-880.
[56] Graner M, Raymond A, Romney D, He L, et al. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma [J]. Clin Cancer Res, 2000, 6:909-915.
[57] Graner M, Raymond A, Romney D, He L, et al. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma [J]. Clin Cancer Res, 2000, 6:909-915.
[58] Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma [J]. Clin Cancer Res, 2000, 6:909-915.
[59] Granja C, Moliterno RA, Ferreira MS, et al. T-cell autoreactivity to Hsp in human transplantation may involve both proinflammatory and regulatory functions [J]. Hum Immunol, 2004, 65(2):124-134.
[60] Gup ta S, Knowlton AA. HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway [J]. Am J Physiol Heart Circ Physiol, 2007, 292:3052-3056.
[61] Gup ta S, Knowlton AA. HSP60, Bax, apop tosis and the heart [J]. J CellMolMed, 2005, 9:51-58.
[62] Hanahan D, Weinberg R A. The hallmarks of cancer [J]. Cell, 2000, 100(1): 572-601.
[63] Hant S O, Superti F G. Regulation of the c-Ab1 and Bcr-Ab1 tyrosine kinases [J]. Nat Rev Mol Cell Biol, 2004, 5(1):33-44.
[64] Harrop R, John J, Carroll M W. Recombinant viral vectors: Cancer vaccines [J]. Adv Drug Deliv Rev, 2006, 58(8):931-947.
[65] Heath A W, Playfair J H. Cytokines as immunological adjuvants [J]. Vaccine, 1992, 10(7):427-434.
[66] Heath, W R, Belz G. T, Behrens G. M, et al. Cross-presentation, dendriticcell subsets, and the generation of immunity to cellular antigens [J]. Immunol Rev, 2004, 199(6):9-26.
[67] Heikema A, Agsteribbe E, Wiscjut J, et al. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides [J]. J Immunol Lett, 1997, 57:69-74.
[68] Henderson R A, Watkins S C, Flynn J L. Activation of human dendritic cells following infection with Mycobacterium tuberculosis [J]. J Immunol, 1997, 159 (2):635-643.
[69] Herbert W J. Mineraloil adjuvants and the immunization of laboratory animals [M]. In: Weir D M. Handbook of Experimental Immunology. 3rd edition. Oxford: Blackwell Scientific Publications, 2003:A 3.12-A 3.15.
[70] Hompson P L, Dessureault S. Tumor cell vaccines [J]. Adv Exp Med Biol, 2007, 601:345-355.
[71] Hsu F J, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells [J]. Nat Med, 1996, 2(1):52-58.
[72] Hsueh E C, Morton D L. Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine [J]. Semin Cancer Biol, 2003, 13(6): 401-407.
[73] Huang DB, Wu J J, Tyring S K. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines [J]. 2004, Infect, 49: 179–209.
[74] Igor E D. Cancer Vaccines [J]. The Oncologist, 2002, 7:20-33.
[75] Isabella R, Barbara K, Gunter S. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities [J]. J Immunol, 1999, 163: 1730-1732.
[76] Ishii T, Vdono H, Yamano T, et al. Isolation of MHC class I-restricted tumor antieng peptide and its precursors associated with heat shock proteins HSP70, HSP90 and gp96 [J]. J Immunol, 1999, 162:1303-1309.
[77] Ivan Roitt. Essential immunology, 9 th ed [M]. Oxford: Blackwell Science, 1997: 3032305.
[78] Janetzki S, Palla D, Rosenhauer V, et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study [J]. Int J Cancer, 2000, 88(2):232-238.
[79] Janetzki S, Palla D, Rosenhauer V, et al. Immunization of cancer patients with autologous cancer derived heat shock protein gp96 preparations: A pilot study [J]. Int J Cancer, 2000, 88(2):232-238.
[80] Jiao W, Li P , Zhang J , et al . Small heat-shock proteins function in the insoluble protein complex [J]. Biochem Biophys Res Commun, 2005, 335(1):227-231.
[81] Jin Z G, Melaragno M G, Liao D F, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress [J]. Circ Res, 2000, 87(9):789-796.
[82] Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial [J]. Lancet, 2004, 363(9409):594-599.
[83] Kamal A, Thao L, Sensintaffar J, et al. A high affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors [J]. Nature, 2003, 425(6956): 407-410.
[84] Kaufmann S. Heat shock proteins and the immune response [J]. Immunol Today, 1990, 11:129-136.
[85] Kedersha N L, Gupta M, Li W, et al. RNΑ-binding proteins TIA-1 and TIAR link the phophorylation of Eif-2 alpha to the assembly of mammalian stress granules [J]. J Cell Biol, 1999, 147(7):1431-1442.
[86] Kerri L K, Marilyn T M, Gang L, et al. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia [J]. FASEB, 2007, 21:2173-2184.
[87] Khanna R. Tumour surveillance: Missing peptides and MHC molecules [J].Immunol and Cell Biol, 1998, 76(1):20-26.
[88] Kirchhoff S R, Gupta S, Knowlton A A. Cytosolic Heat Shock Protein 60, Apoptosis, and Myocardial Injury [J]. Circulation, 2002,105:2899-2904.
[89] Klettner A. The induction of heat shock proteins as a potential strategy to treat neurodegenerative disorders [J]. Drug News Perspect, 2004, 17:299-306.
[90] Krause S W, Gastpar R, Andreesen R, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: A clinical phase I trial [J]. Clin Cancer Res, 2004, 10(11): 3699–3707.
[91] Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids [J]. Nat Med, 2000, 6(3):332-336.
[92] Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surfaceimmunoglobulin idiotype expressed by their tumors [J]. N Engl J Med, 1992, 327:1209-1215.
[93] Lamb J R, Bal V, Mendez S A, et al. Stress proteins may provide a link between the immune response to infection and autoimmunity [J]. Int Immunol, 1989, 1:191-196.
[94] Larregina A T, Watkins S C, Erdos G, et al. Direct transfection and activation of human cutaneous dendritic cells [J]. Gene Ther, 2001, 8(8):608-617.
[95] Lee S T, Jiang Y F, Park K U, et al. Biovax ID: a personalized therapeutic cancer vaccine for non-Hodgkin’s lymphoma [J]. Expert Op in Biol Ther, 2007, 7(1):113-122.
[96] Lewis S E, Mannion R T, White F A, et al. A role for HSP27 in sensory meuron survival [J]. J Neurosci, 1999, 19(20):8945-8953.
[97] Li G, Xie L, Zhou G, et al. A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients [J]. ChinMed J, 2002, 115(4):567-570.
[98] Li G, Zeng Y, Chen X, et al. Human ovarian tumour-derivedchaperone-rich cell lysate (CRCL) elicits T cell responses in vitro [J]. Cli Exp Immunol, 2007, 148:136-145.
[99] Li L, Giannopoulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts [J]. Int J Oncol, 2006, 28(4):855-861.
[100] Li Z, Qiao Y, Gaffney U, et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein 70 vaccine for chronic myelogenous leukemia [J]. Proc Am Soc Clin Oncol, 2003, 22:166-174.
[101] Liann G K, George C T. Heat shock protein 70 kDa: Molecular biology, bioche mistry and physiology [J]. Pharmacol Ther, 1998, 80(2):183—201.
[102] Liao D F, Jin Z G, Baas A S, et al. Purification and identification of secreted oxidative stress induced factors from vascular smooth muscle cells [J]. J Biol Chem, 2000, 275(1):189-196.
[103] Liénard D, Rimoldi D, Marchand M, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA [J]. Cancer Immun, 2004, 4:4-10.
[104] Lima J, Jenkins C, Guerrero A, et al. A DNA vaccine encoding genetic fusions of carcino embryonic antigen (CEA) and granulocyte/macrophage colony stimulating factor (GM-CSF) [J]. Vaccine, 2006, 23(10):1273- 1283.
[105] Limacher J M, Acres B. MUC1, a therapeutic target in oncology [J]. Bull Cancer, 2007, 94(3):253-257.
[106] Lin M I, Fulton D, Babbitt R, et al. Phosphorylation of threonine 497 in endothelial nitric2oxide synthase coordinates the coupling of Larginine metabolism to efficient nitric oxide production [J]. J Biol Chem, 2003, 278(45):44719-44726.
[107] Losser D, Caron A W, Bourgert L, et al. The chaperone function of HSP70 is required for protection against stress-induced apoptosis [J]. Mol Cell Biol,2000,20(19):7146-7159.
[108] Lou Y M, Seipp P R, Cai B, et al. Tumor immunity and T cell memory are induced by low dose inoculation with a non replicating adenovirus encoding TAP 1[J]. Vaccine, 2007, 25:2331-2339.
[109] Luis E R, Steven F, Eckhard R P. Lung Cancer Immunotherapy [J]. Clini Med & Res, 2005, 3(4): 221-228.
[110] Macary P A, Javid B, Floto R A, et al [J]. HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity, 2004, 20:95–106.
[111] Maloney A , Workman P. HSP90 as a new therapeutic target for cancer therapy : the story unfolds [J]. Expert Opin Biol Ther, 2002, 2(1):322-341.
[112] Mao C. Efficacy of human pap illomavirus-16 vaccine to prevent cervical intraepithecial neoplasia: a randomized controlled trial [J]. Obstet Gynecol, 2006, 107:18-27.
[113] Marchand M, Punt C J, Aamdal S, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report [J]. Eur J Cancer, 2003, 39:70-77.
[114] Mazzaferro V, Coppa J, Carrabba M G, et al. Vaccination with autologous tumor-derived heat shock protein gp96 after liver resection for metastatic colorectal cancer [J]. Clin Cancer Res, 2003, 9(9):3235-3245.
[115] McNicholl J M, Bond K B, Ruhadze E R et al. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants (I):Induction of high titer, long lasting, cross reactive antibodies of broad isotype [J]. AIDS Res Hum Retroviruses, 1998, 14(16):1457-1471.
[116] Michael W G, Yi Z, Hanping F, et al. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers [J]. Cancer Immunol Immunother, 2003, 52:226-234.
[117] Millar D G, Garza K M, Odermatt B, et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo [J]. Nat Med. 2003, 9(12):1469-1476.
[118] Miyata Y, Ikawa Y, Shibuya M, et al. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen activated protein kinase super family [J]. J Biol Chem, 2001,276(24):21841-21848.
[119] Moret T I, Sanmartin I, Marco F M, et al. Nonviral therapeutic cell vaccine mediates potent antitumor effects [J]. Vaccine, 2006, 24(18): 3937-3945.
[120] Morimoto R I, Tissieres A, Ceorgopoulos C. The stress response, function 0f the proteins, and perspectives [A]. Morimoto R I et al. Stress Proteins in Biology andMedicine[C]. Cold Spring Harbor: CSIR Press, 1990, 1-36.
[121] Murphy G P, Tjoa B A, Simmons S J, et al. PhaseⅡprostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment [J]. Prostate, 1999, 39(1):54-59.
[122] Nadine C F, Anne L, Caroline F. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo [J]. Nature Med, 1999, 5(4): 405-411.
[123] Nair S, Wearsch P A, Mitchell D A, et al. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides [J]. J Immunol, 1999, 162:6426-6432.
[124] Nakamoto H , Vigh L. The small heat shock proteins and their clients [J] . Cell Mol Life Sci, 2007, 64(3):294-306.
[125] Nemunaitis J, Nemunaitis J. A review of vaccine clinical trials for non -small cell lung cancer [J]. Expert Op in Biol Ther, 2007, 7(1):89-102.
[126] Niethammer A G, Primus F J, Xiang R, et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice [J]. Vaccine, 2001, 20(3- 4):421-429.
[127] Nylandskd J , Brank K, J aattela I , et a1. Heat shock protein 70 is required for the survivallf canncer cell [J]. Ann Natl Acad Sci, 2000, 926:122-125.
[128] Pellicciari C, Bottone M G, Scovassi A I, et al. Rearrangement of nuclear ribonucleoproteins and extrusion of nucleolus-like bodies during apoptosis induced by hypertonic stress [J]. Eur J Hisochem, 2000, 44:247-249.
[129] Penelope A, Shepherd. Immunotherapy for Lung Cancer Bradbury [J]. FRCPC, 2008, 3(6):164-170.
[130] Peoples G E, Gurney J M, Hueman M T, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients [J]. J Clin Oncol, 2005, 23(30):7536-7545.
[131] Raez L E, Cassileth P A, Schlesslman JJ, et al. Allogeneic vaccination with a B7. 1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small cell lung cancer [J]. J Clin oncol, 2004, 22:2800-2807.
[132] Raska M, Weigl E. Heat shock proteins in autoimmune diseases [J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2005,149(2):243-249.
[133] Reichardt V L, Milazzo C, Brugger W, et al. Idiotype vaccination of multiple myeloma patients using monocytederived dendritic cells [J]. Haematologica, 2003, 88(10):1139-1149.
[134] Reinartz S, Kêhler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II) [J]. Clin Cancer Res, 2004, 10(5):1580-1587.
[135] Rossmann A, Henderson B, Heidecker B, et al. T-cells from advanced atherosclerotic lesions recognize hHSP60 and have a restricted T-cell receptor repertoire [J]. Exp Gerontol, 2008, 43(3):229-237.
[136] Samali A, Jiyang C, Boris Z, et al. Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of Jurkat cells [J]. J EMBO, 1999, 18:2040–2048.
[137] Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer [J]. Clin Cancer Res, 2007, 13(15):4652-4654.
[138] Schadendorf D, Ugurel S, Schuler T B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phaseⅢtrial of the DC study group of the DeCOG [J]. Ann Oncol, 2006, 17(4):563-570.
[139] Schmitt E, Gehrmann M, Brunet M, et al. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy [J]. J Leuko Bio, 2007, 81: 15-27.
[140] Sfondrini L, Balsari A and Me′nard S. Innate immunity in breast carcinoma [J]. Endocrine-Related Cancer, 2003, 10:301–308.
[141] Shi F F, Gunn R G, Snyder A L, et al. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases [J]. Vaccine, 2007, 25:3338-3346.
[142] Skinner M A, Prestidge R, Yuan S, et al. The ability of heat-killed Mycobacterium vaccae to stimulate a cytotoxic T-cell response to an unrelated protein is associated with a 65 kilodalton heat-shock protein [J]. Immunology, 2001, 102(2):225–233.
[143] Solit D B, Scher H I, Rosen N. HSP90 as a therapeutic target in prostate cancer [J]. Semin Oncol, 2003, 30(5): 709-716.
[144] Sondak V K, Sosman J A. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine:Melacine [J]. Semin Cancer Biol, 2003, 13(6):409-415.
[145] Soti C, Nagy E, Giricz Z, et al. Heat shock proteins as emerging therapeutic targets [J]. Br J Pharmacol, 2005, 146:769-780.
[146] Srivastava P K, Amato R J. Heat shock proteins:the‘Swiss Army Knife' vaccines against cancers and infectious agents [J]. Vaccine, 2001, 19:2590-2597.
[147] Srivastava P K, DeLeo A B, Old L J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci, 1986, 83(10):3407-3411.
[148] Srivastava P K, Old L J. Individually distinct transplantation antigens of chemically induced mouse tumors [J]. Immunol Today, 1988, 9(3):78-83.
[149] Srivastava P K. Do human cancers express shared protective antigens? or the necessity of remembrance of things past [J]. Semin Immunol, 1996, 8(5):295-302.
[150] Srivastava P K. Immunotherapy of human cancer:lessons from mice [J]. Nat Immunol, 2000, 1(5):363-366.
[151] Srivastava P K. Immunotherapy of human cancer:lessons from mice [J]. Nat Immunol, 2000, 1(5):363-366.
[152] Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses [J]. Annual Review of Immunology, 2002, 20:395-425.
[153] Staats H F, Ennis F A J. IL-21 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens [J]. J Immunol, 1999, 162(10):6141-6147.
[154] Suto R, Srivastava P K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science, 1995, 269:1585-1588.
[155] Suzue K, Young R A. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24 [J]. J Immunol, 1996; 156:873-879.
[156] Tabi Z, Man S. Challenges for cancer vaccine development [J]. Adv Drug Deliv Rev, 2006, 58(8):902-915.
[157] Tagliabue A, Rappuoli R.Vaccine adjuvants: the dream becomes real [J]. Hum Vaccin, 2008, 4(5): 347-349.
[158] Takahashi S, Mendelsohn M E. Synergistic activation of endothelial nitricoxide synthase (eNOS) by HSP90 and Akt: calciumin dependent eNOS activation involves formation of an HSP902Akt-CaM-bound eNOS complex [J]. J Biol Chem, 2003, 278(33):30821-30827.
[159] Tamura Y, Peng P, Liu K, et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations [J]. Science, 1997, 278(5335):117-120.
[160] Tamura Y, Peng P, LiU K, et al. Immunotherapy of tumors with autologous tumor derived heat shoek protein preparations [J]. Science, 1997, 278(5335): 117-120.
[161] Tanaka Y, Kanai F, Kawakami T, et al. Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis [J]. Biochem Biophys Res Commun, 2004, 318(2):461-469.
[162] Tetsuya A, Sadao G, Ken H. Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells [J]. BBA,1445(1):123-1333.
[163] Thomas B H, Michaela S, Peter K, et al. Heat shock treatment of tumor lysate-pulsed DCs enhances their capacity to elicit antitumor T-cell responses against medullary thyroid carcinoma [J]. J Clin Endocrin Metab, 2006, 91(11):4571-4577.
[164] Thurner B, Haendle I, Rider C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stageⅣmelanoma [J]. J Exp Med, 1999, 190(11):1669-1678.
[165] Timmerman J M, Czerwinski D K, Davis T A, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients [J]. Blood, 2002, 99(5):1517-1526.
[166] Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects [J]. Br J Haematol, 2000, 108(4):805-816.
[167] Todryk S M, Gough M J, Pockley A G. Facets of heat shock protein 70 show immunotherapeutic potential [J]. Immunology, 2003, 110(1):1-9.
[168] Trimble C, L in C T, Hung C F, et al. Comparison of the CD8+ T cell response and antitumor effects generated by DNA vaccine administed through gene gun, biojector and syringe [J]. Vaccine, 2003, 21(25-26):4036-4042.
[169] Uylde G C, Vermorken J B, Hanna M G J, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a p rospective study ofmedical and economic benefits [J]. Vaccine, 2005, 23(17- 18):2379-2387.
[170] Van B N, Bonnet M C, Dreno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells [J]. J Clin Oncol, 2005, 23(35):9008- 9021.
[171] Van E W, Vander Z R, Paul A, et al. Do heat shock proteins control the balance of T-cell regulation in inflammatory diseases? [J]. Immunol Today, 1998, 19:303-307.
[172] Vande K F A, De Jong W W. The small heat shock proteins Hsp20 and alpha B-crystallin in cultured cardiac myocytes: differences in cellular localizationand solubilization after heat stress [J]. Eur J Cell Biol, 1999, 78(8):567-572.
[173] Vernon K, Sondak A, Jeffrey A. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine? [J]. Sosmanb Seminars in Cancer Biology, 2003, 13:409-415.
[174] Vígh L, Têrêk Z, Balogh G, et al. Membrane-regulated stress response: a theoretical and practical approach [J]. Adv Exp Med Biol, 2007, 594:114-131.
[175] Villinger F. Cytokines as clinical adjuvants: how far are we [J].Expert Rev Vaccines, 2003, 2(2):317-326.
[176] Wei J G, Kentc G G. Loss of Hsp70 in Drosophila Is Pleiotropic, With Effects on Thermotolerance, Recovery From Heat Shock and Neurodegeneration [J]. Genetics,2006,172:275- 286.
[177] Wen jie L, Anna R, Gabriela C, et al. Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? [J]. Bio Med Central, 2008, 9:1-8.
[178] Wendling U, Paul L, Vander Z R, et al. A conserved mycobacterial heat shock protein(hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue [J]. J Immunol, 2000, 164:2711-2717.
[179] Whitesell L, Mimnaugh E G, Decosta B, et al. Ihibition of heat shock protein HSP90-pp60v-sre heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation [J].Proc Natl Acad Sci, 1994(9):8324-8328.
[180] William E P. Fundamental immunology [M]. 4th ed. New York: Lippincott Raven, 1998:1387-1427.
[181] William P A. The Innate Immune System in Rheumatoid Arthritis [J]. ARTHRITIS & RHEUMATISM, 2001,44(10):2224-2234.
[182] Yang K, Li D, Luo M, et al. Generation of HSP60-specific regulatory T cell and effect on atherosclerosis [J]. Cell Immunol, 2006, 243(2):90-95.
[183] Yao Q, Nishiuchi R, Li Q, et al. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 throughdestabilization of signal transduction-associated kinases [J]. Clin Cancer Res, 2003, 9(12):4483-4493.
[184] Yi Z, Xinchun C, Nicolas L, et al. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination [J]. Int J Cancer, 2006, 119(11):2624–2631.
[185] Yi Zeng, Michael W G, Emmanuel K, et al. Chaperone-rich cell lysates, immune activation and tumor vaccination [J]. Cancer Immunol Immunother, 2006, 55:329-338.
[186] Yoshikawa T, Okada N, Tsujino M, et al. Vaccine Efficacy of Fusogenic Liposomes Containing Tumor Cell-Lysate against Murine B16BL6 Melanoma [J]. Biol Pharm. Bull, 2006, 29(1):100—104.
[187] Yvonne P, Afzal R M, Daniel J K. Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens [J]. 2008, Int J Pharm,364(2):272-280.
[188] Zelle R C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysatepulsed autologous dendritic cells [J]. Clin Cancer Res, 2002, 8(11):3369-3376.
[189] Zeng Y, Feng H, Graner M W, et al. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity [J]. Blood, 2003, 101:4485-4491.
[190] Zeng Y, Feng H, Graner M W, et al. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood, 2003, 101:4485–4491.
[191] Zhang H, Fu X, Jiao W, et al. The association of small heat shock protein Hsp1613 with the plasma membrane of mycobacterium tuberculosis: dissociation of oligomers is a prerequisite [J]. Biochem Biophys Res Commun, 2005, 330(4): 1055-1061.
[192] Zhang L, Pelech S, Uitto V J, et al. Long-term effect of heat shock protein 60 from actinobacillus actinomycetemcomitans on epithelial cell viability and mitogen-activated protein kinases. Infect Immun, 2004, 72:38-45.
[193] Zhang W. Electrochemical treatment of lung cancer [J]. Third Med Mil Sinigo, 2000, 22:37-43.
[194] Zou J, Guo Y, Guettouche T, Smith D F, et al. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell, 1998, 94:471-480.
[195]程翔,童莉.肺癌生物治疗研究进展[J].现代中西医结合杂志. 2006, 15(6):829-831.
[196]高雅娟.热休克蛋白与肿瘤免疫[J].国外医学---免疫学分册, 2000, 23 (5): 290-293.
[197]龚兴国,于红. HSP60的功能[J].生物化学与生物物理进展, 2003, 30(4), 946-947.
[198]郭爱疆,才学鹏.小热休克蛋白家族的研究进展[J].中国兽医科技, 2004, 34(5): .
[199]郭建巍. HSP---肿瘤免疫的分子佐剂[J].国外医学免疫学分册, 2002, 25(4), 181-184.
[200]郭兴中.热耐受机制[J].生命的化学, 1996, 16(2):12-13.
[201]郝葆青,刘鲁蜀,张晓冬. DNA疫苗的研究与应用前景[ J ].华西医学, 2005, 1 (20):197-198.
[202]何凌峰,侯树坤,管考鹏,等.热休克蛋白70在膀胱癌中的表达及与细胞凋亡的关系[J].中华泌尿外科杂志, 2004, 25(6):374-376.
[203]罗晨.疫苗与肿瘤免疫治疗[J].国际病理科学与临床杂志, 2006, 26: 4333-4336.
[204]任宝波,王玉艳,王纯净,等. HSP70家族的分类及基因结构与功能[J].动物医学进展, 2005, (26):98-101.
[205]任莉萍,曹小汉.热休克蛋白研究进展[J].安徽农业科学, 2006, 34(10):2040-2042.
[206]邹小农.中国肺癌流行病学[J].中华肿瘤防治杂志, 2007, 14(12):188-190.
[2] Ai J H, Yang Z, Qiu F Z, et al. Heat shock protein 90 is responsible for hyperdynamic circulation in portal hypertensive rats [J]. World J Gastroenterol, 2003, 9(11):2544-2547.
[3] Alard J E, Dueymes M, Youinou P, et al. Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases [J]. Autoimmun Rev, 2007, 6:438-443.
[4] Albanell J, Codony J, Rovira A, et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4 [J]. Adv Exp Med Biol, 2003, 532:2532-2551.
[5] Amato R J. Renal cell carcinoma:review of novel single-agent therapeutics and combination regimens [J]. Ann Oncol, 2005, 16(1):7-15.
[6] Antonia S, MuléJ J, Weber J S. Current developments of immunotherapy in the clinic [J]. Curr Opin Immunol, 2004, 16(2):130- 136.
[7] Arrigo A P, Firdaus WJ, Mellier G, et al. Cytotoxic effects induced by oxidative stress in cultured mammalian cells and protection provided by Hsp27 expression [J]. Methods, 2005, 35(2):126-138.
[8] Assikis V J, Daliani D, Logothetis C, et al. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC) [J]. Proc Am Soc Clin Oncol, 2003, 22:386-393.
[9] Ayada K, Yokota K, Kobayashi K, et al. Chronic infections and atherosclerosis [J]. Ann N Y Acad Sci, 2007, 1108:594-602.
[10] Banchereau J, Palucka A K. Dendritic cells as therapeutic vaccines against cancer [J]. Nat Rev Immunol, 2005, 5(4):296-306.
[11] Barral J M, Broadley S A, Schaffar G, et al. Roles of molecular chaperones in protein misfolding diseases [J]. Semin Cell Dev Biol, 2004, 15:17-29.
[12] Basha E, Friedrich K L, Vierling E. The N-terminal arm of small heat shock proteins is important for both chaperone activity and substrate specificity [J]. J Biol Chem, 2006, 281(52):39943-39952.
[13] Basha E, Lee G J, Demeler B, et al. Chaperone activity of cytosolic small heat shock proteins fromwheat [J]. Eur J Biochem, 2004, 271(8):1426-1436.
[14] Bech M, Plm II, Welch W J. Interaction of folding and assen by events [J]. Science, 1990, 248:850-854.
[15] Behboudi S, Morein B, Villacres E M. In vitro activation of antigen p resenting cells (APC) by defined composition of quillaja saponaria molina triterpenoids [J]. Clin Exp Immunol, 1996, 105:26-30.
[16] Beliakof J, Bagatel R, Paine M G, et al. Hormone refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors [J]. Clin Cancer Res, 2003, 9(13):4961-4971.
[17] Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings [J]. J Clin Oncol, 2002, 20(20):4169-4180.
[18] Bendandi M, Rodríguez-Calvillo M, Inogés S, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation [J]. Leuk Lymphoma, 2006, 47(1):29-37.
[19] Bergstrom M M, Lovgren K, Akerblom L. Antigen specific increases in the number of splenocyttes expressing MHC classⅡmolecules following restimulation with antigen in various physical forms [J]. Scand J Immunol, 1992, 36:565-574.
[20] Blachere N E, Li Z L, Chandawarkar R Y, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity [J]. J Exp Med, 1997, 186:1315-1322.
[21] Blachere N E, Udono H, Janetzki S, et al. Heat shock protein vaccinesagainst cancer [J]. J Immunother, 1993, 14:352-356.
[22] Bradbury, Penelope A, Shepherd, Immunotherapy for Lung Cancer [J]. FRCPC, 2008, 3(6):164-170.
[23] Butts C, Murray N, Maksymiuk A. Randomized phase IIB trial of BLP25 liposome vaccine instage IIIB and IV non-small cell lung cancer [J]. J Clin Oncol, 2005, 23(27):6674-6681.
[24] Capdeville R, Silberman S. Imatinib: a targeted clinical drug development [J]. Semin Hematol, 2003, 40(2):15-20.
[25] Carmody R J, Chen Y H. Nuclear factor-kappaβ: activation and regulation during toll-like receptor signaling [J]. Cell Mol Immunol, 2007, 4:31-41.
[26] Carolina M, Keith H, David S. L. Heat shock proteins hsp90 and hsp70 protect neuronal cells from thermal stress but not from programmed cell death. [J] Neuro Chem, 1994, 63:1787-1795.
[27] Cerundolo V, Hermans I F, Salio M. Dendritic cells:a journey from laboratory to clinic [J]. Nat Immunol, 2004, 5(1):7-10.
[28] Chandawarkar R Y, Wagh M S, Srivastava P K. The dual nature of specific immunological activity of tumor-derived gp96 preparations [J]. J Exp Med, 1999, 189(9):1437-1442.
[29] Chen W, Syldath U, Bellmannk, et al. Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System[J]. J Immunol, 1999, 162(6):3212-3219.
[30] Chu N R,Wu H B, Wu T C, et al. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7 [J]. Cell Stress & Chaperones,2000,5(5):401-405.
[31] Ciupitu A T, Petersson M, Donnell C L, et al. Immunization with a lymphocytic choriomeningitisvirus peptide mixed with heat shock protein 70 resultsin protective antiviral immunity and specific cytotoxic T lymphocytes [J]. J Exp Med, 1998, 187:685-691.
[32] Conry R M, Curiel D T, Strong T V, et al. Safety and immunogenicity of aDNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients [J]. Clin Cancer Res, 2002, 8(9): 2782-2787.
[33] Curti A, Tosi P, Comoli P, et al. PhaseⅠ/Ⅱclinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides [J]. Br J Haematol, 2007, 139(3):415-424.
[34] Dadabayev A R, Wang Z, Zhang Y, et al. Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics? [J]. Am J Hematol, 2005, 80(1):6-11.
[35] Daniel P S, Abba I T, Tristram G P. Basic & Clinical Immunology, 8 th ed [M]. East Norwalk: Prentice Hall International Inc, 1994:51-52.
[36] Dapeng L, Hui L, Peiyin Z, et al. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity [J]. Eur J Immunol, 2006, 36: 1324-1336.
[37] David S, Manuel G, Francisco S M. CD69 is an immunoregulatory molecule induced following activation [J]. Trends Immunol, 2005, 26(3): 136-140.
[38] De Cerio A L, Zabalegui N, Rodríguez C M, et al. Anti-idiotype antibodies in cancer treatment [J]. Oncogene, 2007, 26(25):3594-602.
[39] Den E J, Bennink E J, Doerwald L, et al. Mimicking phosphorylation of the small heat-shock protein alphaB-crystallin recruits the F-box protein FBX4 to nuclear SC35 speckles [J]. Eur J Biochem, 2004, 271(21):4195-4203.
[40] Deocaris CC, Kaul SC, Wadhwa R. On the brotherhood of the mitochondrial chaperonesmortalin and heat shock protein 60 [J]. Cell Stress Chaperones, 2006, 11:116-128.
[41] Donna H D, Kevin T H, Erin M S, et al. The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines [J]. BMC Cancer, 2008, 8(12):360-871.
[42] Dotsika E, Karagouni E, Sundquist B et al. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein Barr virusISCOMs [J]. Scand J Immunol, 1997, 45:261-268.
[43] Dresses R, Dlsner L, Quentin T, et al. Heat shock protein 70 is able to prevent heat shock-jnduced resistance of tragel cells to CTL [J]. J Immunol, 2000, 164(5):2362-2371.
[44] Dudley M E, Wunderlich J R, Yang J C, et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J]. Clin Oncol, 2005, 23(10):2346-2357.
[45] Dunn G P, Bruce A T, Ikeda H, et al. Cancer immunoediting:from immunosurveillance to tumor escape [J]. Nat Immunol, 2002, 3(11):991-998.
[46] Evel K K, Chen S Y. Dendritic cell-based tumor vaccines and antigen presentation attenuators [J]. Mol Ther, 2006, 13(5):850-858.
[47] Faried A, Sohda M, Nakajima M, et al. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma [J]. Eur J Cancer, 2004, 40(18):2804-2811.
[48] Feng H, Zeng Y, Graner M W, et al. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood, 2003, 101:245-252.
[49] Finn O J. Cancer vaccines: between the idea and the reality [J]. Nat Rev Immunol, 2003, 3(8):630-641.
[50] Gang L, Samita A, Gustavo H, et al. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model [J]. Mol Cancer Ther, 2008, 7(3):721-729.
[51] Garcia M, Jemal A, Ward E M, et al. Global Cancer Facts & Figures 2007 [J]. American Cancer Society, 2007, 20:1-52.
[52] Garia S N. Net results of nucleolar dynamics [J]. Cell, 1999, 97:825-828.
[53] Georges H W, Pierre J. Immunostimulating agents: what next? A review of their present and potentialmedical applications [J]. Eur J Biochem, 1996, 242(1):1-19.
[54] Gilboa E. DC-based cancer vaccines [J]. J Clin Invest, 2007, 117(5):1195-1203.
[55] Gorre M E, Mohammed M, Ellwood K, et al. Clinical resistance to STl2571 cancer therapy caused by BCR2 ABL gene mutation or amplification [J]. Science, 2001, 293(5531):876-880.
[56] Graner M, Raymond A, Romney D, He L, et al. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma [J]. Clin Cancer Res, 2000, 6:909-915.
[57] Graner M, Raymond A, Romney D, He L, et al. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma [J]. Clin Cancer Res, 2000, 6:909-915.
[58] Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma [J]. Clin Cancer Res, 2000, 6:909-915.
[59] Granja C, Moliterno RA, Ferreira MS, et al. T-cell autoreactivity to Hsp in human transplantation may involve both proinflammatory and regulatory functions [J]. Hum Immunol, 2004, 65(2):124-134.
[60] Gup ta S, Knowlton AA. HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway [J]. Am J Physiol Heart Circ Physiol, 2007, 292:3052-3056.
[61] Gup ta S, Knowlton AA. HSP60, Bax, apop tosis and the heart [J]. J CellMolMed, 2005, 9:51-58.
[62] Hanahan D, Weinberg R A. The hallmarks of cancer [J]. Cell, 2000, 100(1): 572-601.
[63] Hant S O, Superti F G. Regulation of the c-Ab1 and Bcr-Ab1 tyrosine kinases [J]. Nat Rev Mol Cell Biol, 2004, 5(1):33-44.
[64] Harrop R, John J, Carroll M W. Recombinant viral vectors: Cancer vaccines [J]. Adv Drug Deliv Rev, 2006, 58(8):931-947.
[65] Heath A W, Playfair J H. Cytokines as immunological adjuvants [J]. Vaccine, 1992, 10(7):427-434.
[66] Heath, W R, Belz G. T, Behrens G. M, et al. Cross-presentation, dendriticcell subsets, and the generation of immunity to cellular antigens [J]. Immunol Rev, 2004, 199(6):9-26.
[67] Heikema A, Agsteribbe E, Wiscjut J, et al. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides [J]. J Immunol Lett, 1997, 57:69-74.
[68] Henderson R A, Watkins S C, Flynn J L. Activation of human dendritic cells following infection with Mycobacterium tuberculosis [J]. J Immunol, 1997, 159 (2):635-643.
[69] Herbert W J. Mineraloil adjuvants and the immunization of laboratory animals [M]. In: Weir D M. Handbook of Experimental Immunology. 3rd edition. Oxford: Blackwell Scientific Publications, 2003:A 3.12-A 3.15.
[70] Hompson P L, Dessureault S. Tumor cell vaccines [J]. Adv Exp Med Biol, 2007, 601:345-355.
[71] Hsu F J, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells [J]. Nat Med, 1996, 2(1):52-58.
[72] Hsueh E C, Morton D L. Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine [J]. Semin Cancer Biol, 2003, 13(6): 401-407.
[73] Huang DB, Wu J J, Tyring S K. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines [J]. 2004, Infect, 49: 179–209.
[74] Igor E D. Cancer Vaccines [J]. The Oncologist, 2002, 7:20-33.
[75] Isabella R, Barbara K, Gunter S. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities [J]. J Immunol, 1999, 163: 1730-1732.
[76] Ishii T, Vdono H, Yamano T, et al. Isolation of MHC class I-restricted tumor antieng peptide and its precursors associated with heat shock proteins HSP70, HSP90 and gp96 [J]. J Immunol, 1999, 162:1303-1309.
[77] Ivan Roitt. Essential immunology, 9 th ed [M]. Oxford: Blackwell Science, 1997: 3032305.
[78] Janetzki S, Palla D, Rosenhauer V, et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study [J]. Int J Cancer, 2000, 88(2):232-238.
[79] Janetzki S, Palla D, Rosenhauer V, et al. Immunization of cancer patients with autologous cancer derived heat shock protein gp96 preparations: A pilot study [J]. Int J Cancer, 2000, 88(2):232-238.
[80] Jiao W, Li P , Zhang J , et al . Small heat-shock proteins function in the insoluble protein complex [J]. Biochem Biophys Res Commun, 2005, 335(1):227-231.
[81] Jin Z G, Melaragno M G, Liao D F, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress [J]. Circ Res, 2000, 87(9):789-796.
[82] Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial [J]. Lancet, 2004, 363(9409):594-599.
[83] Kamal A, Thao L, Sensintaffar J, et al. A high affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors [J]. Nature, 2003, 425(6956): 407-410.
[84] Kaufmann S. Heat shock proteins and the immune response [J]. Immunol Today, 1990, 11:129-136.
[85] Kedersha N L, Gupta M, Li W, et al. RNΑ-binding proteins TIA-1 and TIAR link the phophorylation of Eif-2 alpha to the assembly of mammalian stress granules [J]. J Cell Biol, 1999, 147(7):1431-1442.
[86] Kerri L K, Marilyn T M, Gang L, et al. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia [J]. FASEB, 2007, 21:2173-2184.
[87] Khanna R. Tumour surveillance: Missing peptides and MHC molecules [J].Immunol and Cell Biol, 1998, 76(1):20-26.
[88] Kirchhoff S R, Gupta S, Knowlton A A. Cytosolic Heat Shock Protein 60, Apoptosis, and Myocardial Injury [J]. Circulation, 2002,105:2899-2904.
[89] Klettner A. The induction of heat shock proteins as a potential strategy to treat neurodegenerative disorders [J]. Drug News Perspect, 2004, 17:299-306.
[90] Krause S W, Gastpar R, Andreesen R, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: A clinical phase I trial [J]. Clin Cancer Res, 2004, 10(11): 3699–3707.
[91] Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids [J]. Nat Med, 2000, 6(3):332-336.
[92] Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surfaceimmunoglobulin idiotype expressed by their tumors [J]. N Engl J Med, 1992, 327:1209-1215.
[93] Lamb J R, Bal V, Mendez S A, et al. Stress proteins may provide a link between the immune response to infection and autoimmunity [J]. Int Immunol, 1989, 1:191-196.
[94] Larregina A T, Watkins S C, Erdos G, et al. Direct transfection and activation of human cutaneous dendritic cells [J]. Gene Ther, 2001, 8(8):608-617.
[95] Lee S T, Jiang Y F, Park K U, et al. Biovax ID: a personalized therapeutic cancer vaccine for non-Hodgkin’s lymphoma [J]. Expert Op in Biol Ther, 2007, 7(1):113-122.
[96] Lewis S E, Mannion R T, White F A, et al. A role for HSP27 in sensory meuron survival [J]. J Neurosci, 1999, 19(20):8945-8953.
[97] Li G, Xie L, Zhou G, et al. A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients [J]. ChinMed J, 2002, 115(4):567-570.
[98] Li G, Zeng Y, Chen X, et al. Human ovarian tumour-derivedchaperone-rich cell lysate (CRCL) elicits T cell responses in vitro [J]. Cli Exp Immunol, 2007, 148:136-145.
[99] Li L, Giannopoulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts [J]. Int J Oncol, 2006, 28(4):855-861.
[100] Li Z, Qiao Y, Gaffney U, et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein 70 vaccine for chronic myelogenous leukemia [J]. Proc Am Soc Clin Oncol, 2003, 22:166-174.
[101] Liann G K, George C T. Heat shock protein 70 kDa: Molecular biology, bioche mistry and physiology [J]. Pharmacol Ther, 1998, 80(2):183—201.
[102] Liao D F, Jin Z G, Baas A S, et al. Purification and identification of secreted oxidative stress induced factors from vascular smooth muscle cells [J]. J Biol Chem, 2000, 275(1):189-196.
[103] Liénard D, Rimoldi D, Marchand M, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA [J]. Cancer Immun, 2004, 4:4-10.
[104] Lima J, Jenkins C, Guerrero A, et al. A DNA vaccine encoding genetic fusions of carcino embryonic antigen (CEA) and granulocyte/macrophage colony stimulating factor (GM-CSF) [J]. Vaccine, 2006, 23(10):1273- 1283.
[105] Limacher J M, Acres B. MUC1, a therapeutic target in oncology [J]. Bull Cancer, 2007, 94(3):253-257.
[106] Lin M I, Fulton D, Babbitt R, et al. Phosphorylation of threonine 497 in endothelial nitric2oxide synthase coordinates the coupling of Larginine metabolism to efficient nitric oxide production [J]. J Biol Chem, 2003, 278(45):44719-44726.
[107] Losser D, Caron A W, Bourgert L, et al. The chaperone function of HSP70 is required for protection against stress-induced apoptosis [J]. Mol Cell Biol,2000,20(19):7146-7159.
[108] Lou Y M, Seipp P R, Cai B, et al. Tumor immunity and T cell memory are induced by low dose inoculation with a non replicating adenovirus encoding TAP 1[J]. Vaccine, 2007, 25:2331-2339.
[109] Luis E R, Steven F, Eckhard R P. Lung Cancer Immunotherapy [J]. Clini Med & Res, 2005, 3(4): 221-228.
[110] Macary P A, Javid B, Floto R A, et al [J]. HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity, 2004, 20:95–106.
[111] Maloney A , Workman P. HSP90 as a new therapeutic target for cancer therapy : the story unfolds [J]. Expert Opin Biol Ther, 2002, 2(1):322-341.
[112] Mao C. Efficacy of human pap illomavirus-16 vaccine to prevent cervical intraepithecial neoplasia: a randomized controlled trial [J]. Obstet Gynecol, 2006, 107:18-27.
[113] Marchand M, Punt C J, Aamdal S, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report [J]. Eur J Cancer, 2003, 39:70-77.
[114] Mazzaferro V, Coppa J, Carrabba M G, et al. Vaccination with autologous tumor-derived heat shock protein gp96 after liver resection for metastatic colorectal cancer [J]. Clin Cancer Res, 2003, 9(9):3235-3245.
[115] McNicholl J M, Bond K B, Ruhadze E R et al. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants (I):Induction of high titer, long lasting, cross reactive antibodies of broad isotype [J]. AIDS Res Hum Retroviruses, 1998, 14(16):1457-1471.
[116] Michael W G, Yi Z, Hanping F, et al. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers [J]. Cancer Immunol Immunother, 2003, 52:226-234.
[117] Millar D G, Garza K M, Odermatt B, et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo [J]. Nat Med. 2003, 9(12):1469-1476.
[118] Miyata Y, Ikawa Y, Shibuya M, et al. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen activated protein kinase super family [J]. J Biol Chem, 2001,276(24):21841-21848.
[119] Moret T I, Sanmartin I, Marco F M, et al. Nonviral therapeutic cell vaccine mediates potent antitumor effects [J]. Vaccine, 2006, 24(18): 3937-3945.
[120] Morimoto R I, Tissieres A, Ceorgopoulos C. The stress response, function 0f the proteins, and perspectives [A]. Morimoto R I et al. Stress Proteins in Biology andMedicine[C]. Cold Spring Harbor: CSIR Press, 1990, 1-36.
[121] Murphy G P, Tjoa B A, Simmons S J, et al. PhaseⅡprostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment [J]. Prostate, 1999, 39(1):54-59.
[122] Nadine C F, Anne L, Caroline F. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo [J]. Nature Med, 1999, 5(4): 405-411.
[123] Nair S, Wearsch P A, Mitchell D A, et al. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides [J]. J Immunol, 1999, 162:6426-6432.
[124] Nakamoto H , Vigh L. The small heat shock proteins and their clients [J] . Cell Mol Life Sci, 2007, 64(3):294-306.
[125] Nemunaitis J, Nemunaitis J. A review of vaccine clinical trials for non -small cell lung cancer [J]. Expert Op in Biol Ther, 2007, 7(1):89-102.
[126] Niethammer A G, Primus F J, Xiang R, et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice [J]. Vaccine, 2001, 20(3- 4):421-429.
[127] Nylandskd J , Brank K, J aattela I , et a1. Heat shock protein 70 is required for the survivallf canncer cell [J]. Ann Natl Acad Sci, 2000, 926:122-125.
[128] Pellicciari C, Bottone M G, Scovassi A I, et al. Rearrangement of nuclear ribonucleoproteins and extrusion of nucleolus-like bodies during apoptosis induced by hypertonic stress [J]. Eur J Hisochem, 2000, 44:247-249.
[129] Penelope A, Shepherd. Immunotherapy for Lung Cancer Bradbury [J]. FRCPC, 2008, 3(6):164-170.
[130] Peoples G E, Gurney J M, Hueman M T, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients [J]. J Clin Oncol, 2005, 23(30):7536-7545.
[131] Raez L E, Cassileth P A, Schlesslman JJ, et al. Allogeneic vaccination with a B7. 1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small cell lung cancer [J]. J Clin oncol, 2004, 22:2800-2807.
[132] Raska M, Weigl E. Heat shock proteins in autoimmune diseases [J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2005,149(2):243-249.
[133] Reichardt V L, Milazzo C, Brugger W, et al. Idiotype vaccination of multiple myeloma patients using monocytederived dendritic cells [J]. Haematologica, 2003, 88(10):1139-1149.
[134] Reinartz S, Kêhler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II) [J]. Clin Cancer Res, 2004, 10(5):1580-1587.
[135] Rossmann A, Henderson B, Heidecker B, et al. T-cells from advanced atherosclerotic lesions recognize hHSP60 and have a restricted T-cell receptor repertoire [J]. Exp Gerontol, 2008, 43(3):229-237.
[136] Samali A, Jiyang C, Boris Z, et al. Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of Jurkat cells [J]. J EMBO, 1999, 18:2040–2048.
[137] Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer [J]. Clin Cancer Res, 2007, 13(15):4652-4654.
[138] Schadendorf D, Ugurel S, Schuler T B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phaseⅢtrial of the DC study group of the DeCOG [J]. Ann Oncol, 2006, 17(4):563-570.
[139] Schmitt E, Gehrmann M, Brunet M, et al. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy [J]. J Leuko Bio, 2007, 81: 15-27.
[140] Sfondrini L, Balsari A and Me′nard S. Innate immunity in breast carcinoma [J]. Endocrine-Related Cancer, 2003, 10:301–308.
[141] Shi F F, Gunn R G, Snyder A L, et al. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases [J]. Vaccine, 2007, 25:3338-3346.
[142] Skinner M A, Prestidge R, Yuan S, et al. The ability of heat-killed Mycobacterium vaccae to stimulate a cytotoxic T-cell response to an unrelated protein is associated with a 65 kilodalton heat-shock protein [J]. Immunology, 2001, 102(2):225–233.
[143] Solit D B, Scher H I, Rosen N. HSP90 as a therapeutic target in prostate cancer [J]. Semin Oncol, 2003, 30(5): 709-716.
[144] Sondak V K, Sosman J A. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine:Melacine [J]. Semin Cancer Biol, 2003, 13(6):409-415.
[145] Soti C, Nagy E, Giricz Z, et al. Heat shock proteins as emerging therapeutic targets [J]. Br J Pharmacol, 2005, 146:769-780.
[146] Srivastava P K, Amato R J. Heat shock proteins:the‘Swiss Army Knife' vaccines against cancers and infectious agents [J]. Vaccine, 2001, 19:2590-2597.
[147] Srivastava P K, DeLeo A B, Old L J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci, 1986, 83(10):3407-3411.
[148] Srivastava P K, Old L J. Individually distinct transplantation antigens of chemically induced mouse tumors [J]. Immunol Today, 1988, 9(3):78-83.
[149] Srivastava P K. Do human cancers express shared protective antigens? or the necessity of remembrance of things past [J]. Semin Immunol, 1996, 8(5):295-302.
[150] Srivastava P K. Immunotherapy of human cancer:lessons from mice [J]. Nat Immunol, 2000, 1(5):363-366.
[151] Srivastava P K. Immunotherapy of human cancer:lessons from mice [J]. Nat Immunol, 2000, 1(5):363-366.
[152] Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses [J]. Annual Review of Immunology, 2002, 20:395-425.
[153] Staats H F, Ennis F A J. IL-21 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens [J]. J Immunol, 1999, 162(10):6141-6147.
[154] Suto R, Srivastava P K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science, 1995, 269:1585-1588.
[155] Suzue K, Young R A. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24 [J]. J Immunol, 1996; 156:873-879.
[156] Tabi Z, Man S. Challenges for cancer vaccine development [J]. Adv Drug Deliv Rev, 2006, 58(8):902-915.
[157] Tagliabue A, Rappuoli R.Vaccine adjuvants: the dream becomes real [J]. Hum Vaccin, 2008, 4(5): 347-349.
[158] Takahashi S, Mendelsohn M E. Synergistic activation of endothelial nitricoxide synthase (eNOS) by HSP90 and Akt: calciumin dependent eNOS activation involves formation of an HSP902Akt-CaM-bound eNOS complex [J]. J Biol Chem, 2003, 278(33):30821-30827.
[159] Tamura Y, Peng P, Liu K, et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations [J]. Science, 1997, 278(5335):117-120.
[160] Tamura Y, Peng P, LiU K, et al. Immunotherapy of tumors with autologous tumor derived heat shoek protein preparations [J]. Science, 1997, 278(5335): 117-120.
[161] Tanaka Y, Kanai F, Kawakami T, et al. Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis [J]. Biochem Biophys Res Commun, 2004, 318(2):461-469.
[162] Tetsuya A, Sadao G, Ken H. Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells [J]. BBA,1445(1):123-1333.
[163] Thomas B H, Michaela S, Peter K, et al. Heat shock treatment of tumor lysate-pulsed DCs enhances their capacity to elicit antitumor T-cell responses against medullary thyroid carcinoma [J]. J Clin Endocrin Metab, 2006, 91(11):4571-4577.
[164] Thurner B, Haendle I, Rider C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stageⅣmelanoma [J]. J Exp Med, 1999, 190(11):1669-1678.
[165] Timmerman J M, Czerwinski D K, Davis T A, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients [J]. Blood, 2002, 99(5):1517-1526.
[166] Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects [J]. Br J Haematol, 2000, 108(4):805-816.
[167] Todryk S M, Gough M J, Pockley A G. Facets of heat shock protein 70 show immunotherapeutic potential [J]. Immunology, 2003, 110(1):1-9.
[168] Trimble C, L in C T, Hung C F, et al. Comparison of the CD8+ T cell response and antitumor effects generated by DNA vaccine administed through gene gun, biojector and syringe [J]. Vaccine, 2003, 21(25-26):4036-4042.
[169] Uylde G C, Vermorken J B, Hanna M G J, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a p rospective study ofmedical and economic benefits [J]. Vaccine, 2005, 23(17- 18):2379-2387.
[170] Van B N, Bonnet M C, Dreno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells [J]. J Clin Oncol, 2005, 23(35):9008- 9021.
[171] Van E W, Vander Z R, Paul A, et al. Do heat shock proteins control the balance of T-cell regulation in inflammatory diseases? [J]. Immunol Today, 1998, 19:303-307.
[172] Vande K F A, De Jong W W. The small heat shock proteins Hsp20 and alpha B-crystallin in cultured cardiac myocytes: differences in cellular localizationand solubilization after heat stress [J]. Eur J Cell Biol, 1999, 78(8):567-572.
[173] Vernon K, Sondak A, Jeffrey A. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine? [J]. Sosmanb Seminars in Cancer Biology, 2003, 13:409-415.
[174] Vígh L, Têrêk Z, Balogh G, et al. Membrane-regulated stress response: a theoretical and practical approach [J]. Adv Exp Med Biol, 2007, 594:114-131.
[175] Villinger F. Cytokines as clinical adjuvants: how far are we [J].Expert Rev Vaccines, 2003, 2(2):317-326.
[176] Wei J G, Kentc G G. Loss of Hsp70 in Drosophila Is Pleiotropic, With Effects on Thermotolerance, Recovery From Heat Shock and Neurodegeneration [J]. Genetics,2006,172:275- 286.
[177] Wen jie L, Anna R, Gabriela C, et al. Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? [J]. Bio Med Central, 2008, 9:1-8.
[178] Wendling U, Paul L, Vander Z R, et al. A conserved mycobacterial heat shock protein(hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue [J]. J Immunol, 2000, 164:2711-2717.
[179] Whitesell L, Mimnaugh E G, Decosta B, et al. Ihibition of heat shock protein HSP90-pp60v-sre heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation [J].Proc Natl Acad Sci, 1994(9):8324-8328.
[180] William E P. Fundamental immunology [M]. 4th ed. New York: Lippincott Raven, 1998:1387-1427.
[181] William P A. The Innate Immune System in Rheumatoid Arthritis [J]. ARTHRITIS & RHEUMATISM, 2001,44(10):2224-2234.
[182] Yang K, Li D, Luo M, et al. Generation of HSP60-specific regulatory T cell and effect on atherosclerosis [J]. Cell Immunol, 2006, 243(2):90-95.
[183] Yao Q, Nishiuchi R, Li Q, et al. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 throughdestabilization of signal transduction-associated kinases [J]. Clin Cancer Res, 2003, 9(12):4483-4493.
[184] Yi Z, Xinchun C, Nicolas L, et al. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination [J]. Int J Cancer, 2006, 119(11):2624–2631.
[185] Yi Zeng, Michael W G, Emmanuel K, et al. Chaperone-rich cell lysates, immune activation and tumor vaccination [J]. Cancer Immunol Immunother, 2006, 55:329-338.
[186] Yoshikawa T, Okada N, Tsujino M, et al. Vaccine Efficacy of Fusogenic Liposomes Containing Tumor Cell-Lysate against Murine B16BL6 Melanoma [J]. Biol Pharm. Bull, 2006, 29(1):100—104.
[187] Yvonne P, Afzal R M, Daniel J K. Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens [J]. 2008, Int J Pharm,364(2):272-280.
[188] Zelle R C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysatepulsed autologous dendritic cells [J]. Clin Cancer Res, 2002, 8(11):3369-3376.
[189] Zeng Y, Feng H, Graner M W, et al. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity [J]. Blood, 2003, 101:4485-4491.
[190] Zeng Y, Feng H, Graner M W, et al. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood, 2003, 101:4485–4491.
[191] Zhang H, Fu X, Jiao W, et al. The association of small heat shock protein Hsp1613 with the plasma membrane of mycobacterium tuberculosis: dissociation of oligomers is a prerequisite [J]. Biochem Biophys Res Commun, 2005, 330(4): 1055-1061.
[192] Zhang L, Pelech S, Uitto V J, et al. Long-term effect of heat shock protein 60 from actinobacillus actinomycetemcomitans on epithelial cell viability and mitogen-activated protein kinases. Infect Immun, 2004, 72:38-45.
[193] Zhang W. Electrochemical treatment of lung cancer [J]. Third Med Mil Sinigo, 2000, 22:37-43.
[194] Zou J, Guo Y, Guettouche T, Smith D F, et al. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell, 1998, 94:471-480.
[195]程翔,童莉.肺癌生物治疗研究进展[J].现代中西医结合杂志. 2006, 15(6):829-831.
[196]高雅娟.热休克蛋白与肿瘤免疫[J].国外医学---免疫学分册, 2000, 23 (5): 290-293.
[197]龚兴国,于红. HSP60的功能[J].生物化学与生物物理进展, 2003, 30(4), 946-947.
[198]郭爱疆,才学鹏.小热休克蛋白家族的研究进展[J].中国兽医科技, 2004, 34(5): .
[199]郭建巍. HSP---肿瘤免疫的分子佐剂[J].国外医学免疫学分册, 2002, 25(4), 181-184.
[200]郭兴中.热耐受机制[J].生命的化学, 1996, 16(2):12-13.
[201]郝葆青,刘鲁蜀,张晓冬. DNA疫苗的研究与应用前景[ J ].华西医学, 2005, 1 (20):197-198.
[202]何凌峰,侯树坤,管考鹏,等.热休克蛋白70在膀胱癌中的表达及与细胞凋亡的关系[J].中华泌尿外科杂志, 2004, 25(6):374-376.
[203]罗晨.疫苗与肿瘤免疫治疗[J].国际病理科学与临床杂志, 2006, 26: 4333-4336.
[204]任宝波,王玉艳,王纯净,等. HSP70家族的分类及基因结构与功能[J].动物医学进展, 2005, (26):98-101.
[205]任莉萍,曹小汉.热休克蛋白研究进展[J].安徽农业科学, 2006, 34(10):2040-2042.
[206]邹小农.中国肺癌流行病学[J].中华肿瘤防治杂志, 2007, 14(12):188-190.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |